View Older Stories

Aug 13, 2026 09:26AM Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Aug 13, 2026 05:39AM Wolfe Research Upgrades Biogen (BIIB) to Outperform

Jul 31, 2026 06:45AM Biogen (BIIB) PT Raised to $251 at H.C. Wainwright

Jul 30, 2026 07:51AM Biogen (BIIB) PT Raised to $248 at Canaccord

Jul 30, 2026 06:42AM Guggenheim Reiterates Buy Rating on Biogen (BIIB)

Jul 29, 2026 01:51PM Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)

Jul 29, 2026 11:15AM Biogen (BIIB) call put ratio 1.7 calls to 1 put into quarter results

Jul 29, 2026 06:07AM Biogen (BIIB) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 EPS Guidance

Jul 28, 2026 11:15AM Biogen (BIIB) call put ratio 1 call to 1 put into quarter results

Jul 21, 2026 05:31AM Biogen (BIIB) PT Lowered to $215 at BofA Securities

Jul 14, 2026 11:15AM Real-world Leqembi study shows 82% of Alzheimer's patients stable

Jul 14, 2026 07:56AM Piper Sandler Reiterates Overweight Rating on Biogen (BIIB)

Jul 13, 2026 08:07AM Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data

Jul 13, 2026 07:30AM Stoke Therapeutics names Thomas McCauley as chief scientific officer

Jul 13, 2026 05:43AM Leqembi subcutaneous data shows similar efficacy to IV in Alzheimer's

Jul 13, 2026 05:05AM Truist Securities Upgrades Biogen (BIIB) to Buy

Jul 1, 2026 04:09PM Biogen expects $164M R&D charge to hit Q2 2026 earnings

Jun 22, 2026 07:33AM Biogen (BIIB) Reiterated at Overweight by Cantor Fitzgerald: Advancing with BIIB080

Jun 18, 2026 07:06AM Needham Reiterates Buy Rating on Biogen (BIIB)

Jun 8, 2026 07:05AM Needham Upgrades Biogen (BIIB) to Buy

Jun 4, 2026 05:54AM UCB and Biogen report positive results for lupus drug dapirolizumab pegol

May 27, 2026 05:42AM Biogen (BIIB) PT Raised to $227 at RBC Capital

May 15, 2026 08:50AM Biogen (BIIB) PT Raised to $225 at Piper Sandler

May 15, 2026 06:38AM Guggenheim Reiterates Buy Rating on Biogen (BIIB)

May 14, 2026 04:59PM Evercore ISI Reinstates Biogen (BIIB) at Outperform

May 14, 2026 12:04PM Biogen (BIIB) PT Raised to $300 at Oppenheimer

May 14, 2026 08:35AM Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'

May 14, 2026 08:17AM Mizuho Reiterates Outperform Rating on Biogen (BIIB)

May 14, 2026 07:44AM Wolfe Research on Biogen (BIIB): 'Re-mem-BIIB-er This Day, BIIB Is Moving Tau Forward'

May 14, 2026 07:29AM Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'

May 14, 2026 07:16AM Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s

May 7, 2026 05:19PM Bright Horizons Family Solutions and Remitly Global to Join S&P SmallCap 600

May 1, 2026 01:05PM Freedom Broker Upgrades Biogen (BIIB) to Buy, raises PT to $245

May 1, 2026 06:52AM H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)

Apr 30, 2026 04:00PM Biogen (BIIB) PT Raised to $190 at Truist Securities

Apr 30, 2026 08:28AM Biogen (BIIB) PT Raised to $222 at RBC Capital

Apr 30, 2026 08:26AM Biogen (BIIB) PT Raised to $196 at Wedbush

Apr 30, 2026 07:35AM Biogen (BIIB) PT Lowered to $200 at Bernstein SocGen Group

Apr 30, 2026 07:12AM Biogen (BIIB) PT Raised to $260 at Guggenheim

Apr 29, 2026 02:58PM Biogen (BIIB) PT Raised to $203 at BofA Securities

Apr 29, 2026 06:18AM Biogen (BIIB) Tops Q1 EPS by 62c; cuts EPS guidance

Apr 27, 2026 09:45AM Truist Securities Reiterates Hold Rating on Biogen (BIIB)

Apr 26, 2026 08:00PM U.S. Biotech stocks: Q1 earnings previews

Apr 24, 2026 03:38PM Biogen (BIIB) PT Raised to $200 at BofA Securities

Apr 22, 2026 09:53AM UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts

Apr 22, 2026 02:46AM UBS Upgrades Biogen (BIIB) to Buy

Apr 20, 2026 07:31AM Biogen acquires TJ Biopharma's felzartamab rights in China for $850M

Apr 13, 2026 05:05PM Piper Sandler Upgrades Biogen (BIIB) to Overweight

Apr 6, 2026 06:36AM Biogen expects $34 million charge in first quarter 2026

Apr 2, 2026 06:43AM Biogen (BIIB) PT Raised to $237 at H.C. Wainwright

View Older Stories